#genetics #cardiomyopathy #dilated-cardiomyopathy #atrial-fibrillation #rare-variants

TTN (Titin)

Overview

TTN encodes titin, the largest protein in the human body (~3.7 MDa), spanning the entire half-sarcomere from Z-disc to M-line. Titin acts as a molecular spring governing passive myocardial stiffness and as a scaffold for sarcomere assembly. Rare loss-of-function (truncating) variants in TTN are the most common monogenic cause of dilated cardiomyopathy (DCM) and the most frequently identified disease-associated variants in patients with early-onset atrial fibrillation.

Epidemiology & Prevalence

DCM — most common gene: TTN truncating variants (TTNtv) account for ~25% of familial DCM and ~18% of sporadic DCM — the single most common monogenic cause of DCM. (sources/esc-cmp-2023, sources/HF-ESC-2021, rating: very high)
Early-onset AF cohort (n = 1293): TTN harbored the most P/LP variants: 38 participants (27% of all disease-associated variants). Median age at AF diagnosis was 44 years (IQR 36–55). This extends Choi 2018 findings of TTN loss-of-function in 2.1% of all early-onset AF and 6.5% in those diagnosed before age 30. (sources/eoaf-jama-2021)
TTNtv yield across EOAF cohorts: TTNtv are present in 4.7% of patients with EOAF onset <40 years, 6.5% in onset <30 years, and 16% in familial AF (Danish cohort, Jurgens et al.). In the largest EOAF panel study (Yoneda et al., n=1293), TTN carried the most P/LP variants (38 participants; 3% of all EOAF), followed by MYH7, MYH6, LMNA, and KCNQ1. (sources/genetic-eoaf-ehj-2024, rating: high)
UK Biobank population-level AF association (n = 403,990): TTN pLOF variants were the strongest and most prevalent rare genetic risk factor for AF. TTN (PSI90 — constitutively expressed cardiac exons) had an OR of 3.85 (95% CI 3.25–4.55; P = 1.09 × 10⁻⁵⁵); TTN cardiac isoforms (N2BA/N2B) OR 2.17; all TTN pLOF variants OR 1.77. (sources/Biobank-AF-JAMA-2024, rating: high)
Combined cardiomyopathy + arrhythmia panel (n = 4,782): TTN was the 2nd most common gene harboring P/LP variants across all cardiomyopathy and arrhythmia subtypes — found in 143 patients (11.7% of all P/LP variants), behind only MYBPC3 (16.7%) and ahead of MYH7 (9.0%). (sources/genetic-yield-jama-card-2022, rating: high)

Variant Classification

Location-dependent pathogenicity: A-band TTNtv: DCM prevalence 10.74% vs. control 0.24%; OR 49.8. Constitutive I-band exons: intermediate risk. Central I-band (low PSI exons): DCM prevalence ~0.24% vs. 0.17% control; OR 1.5 (near-population risk). Restricting to constitutively spliced-in cardiac exons (PSI90) markedly amplifies genetic signal. (sources/TTN-CVResearch-2022, sources/Biobank-AF-JAMA-2024, rating: high)
TTNtv vs. missense — clinical reporting convention: Loss-of-function is the established disease mechanism. Missense variants in TTN are routinely excluded from clinical reporting due to high prevalence and uncertain significance — 494 missense variants excluded in one major EOAF cohort. (sources/eoaf-jama-2021)
VUS burden: 98 TTN loss-of-function VUSs were identified in a single EOAF cohort (the most of any gene). Transcript length mechanically inflates VUS count. Clinical management of a TTN loss-of-function VUS in an AF patient is undefined — no guideline recommends genotype-specific management beyond standard AF care. (sources/eoaf-jama-2021)
Syndrome classification: Variants assigned predominantly to the DCM category; some overlap with AC/ARVC. TTN is on both cardiomyopathy and arrhythmia gene panels of commercial testing laboratories. (sources/eoaf-jama-2021)

Pathophysiology

Sarcomere Architecture

Titin spans the half-sarcomere from Z-disc to M-band as the third sarcomeric filament (alongside myosin and actin). Three functional zones: A-band (inextensible, bound to myosin; serves as thick-filament assembly template); I-band (elastic, contains spring elements); Z-disc/M-band anchor regions. (sources/TTN-CVResearch-2022, rating: high)
The elastic I-band spring contains three extensible elements: PEVK repeats (proline-glutamic acid-valine-lysine), Ig domains (immunoglobulin-like), and the N2B-unique sequence (N2Bus). These elements determine titin's compliance and passive force generation. (sources/TTN-CVResearch-2022, rating: high)
Human TTN has 364 exons (363 in the meta-transcript). Four principal cardiac isoforms: N2B (3 MDa, short/stiff), N2BA (3.2–3.8 MDa, long/compliant), Novex-3 (~650 kDa, structural), Cronos (2.3 MDa, internal promoter, predominantly fetal; ~10% of adult pool). Healthy adult LV: N2BA:N2B ratio ~30:70 to 40:60, stable with normal ageing. See concepts/Titin-Isoform-Switch. (sources/TTN-CVResearch-2022, rating: high)
Titin stiffness regulates length-dependent activation (LDA) — the Frank-Starling mechanism. Stiffer N2B-enriched titin → greater LDA → augmented cardiac output. N2BA-enriched (compliant) titin → blunted LDA → impaired cardiac output, as in HFrEF. (sources/TTN-CVResearch-2022, rating: high)

Post-Translational Modifications (PTMs)

Titin spring stiffness is fine-tuned beat-to-beat through three PTM types. See concepts/Titin-PTMs for full mechanistic detail.

Phosphorylation: N2Bus phosphorylation (PKA/PKG/PKD/ERK2/CaMKIIδ) → decreased stiffness; PEVK phosphorylation (PKCα/CaMKIIδ/PKD) → increased stiffness. In HF: N2Bus hypo-phosphorylation + PEVK hyper-phosphorylation → increased passive stiffness. (sources/TTN-CVResearch-2022, rating: high)
Acetylation: Increased titin acetylation in HFpEF (reduced SIRT1 activity) → increased stiffness. NAD⁺/NAM treatment restores SIRT1 → deacetylation → reduced stiffness in animal models. (sources/TTN-CVResearch-2022, rating: high)
Oxidation (UnDOx): Cryptic cysteines in unfolded Ig domains undergo S-glutathionylation (→ decreased stiffness) or disulphide bonding (→ increased stiffness). In HFpEF/ischaemia, oxidation becomes pathologically extensive. (sources/TTN-CVResearch-2022, rating: high)

TTNtv Cardiomyopathy — Molecular Pathomechanisms

Triple pathomechanism (Fomin et al., Sci Transl Med 2021): (sources/TTN-CVResearch-2022, rating: high)
1. Titin haploinsufficiency: Less wt-titin protein in TTNtv-DCM hearts → fewer sarcomeres per unit area → chronic contractile deficiency.
2. Truncated protein toxicity (poison-peptide mechanism): tr-titin proteins stably expressed in adult TTNtv-DCM hearts (up to 50% of total titin pool); not incorporated into sarcomeres — instead sequestered in cytoplasmic aggregates. Higher tr-titin content correlates with younger age at transplantation.
3. PQC failure: UPS becomes overwhelmed and downregulated (including reduced MuRF1 expression) as disease progresses; aggregate formation activates autophagy as a partial compensatory response. Nonsense-mediated decay of TTNtv mRNA is NOT a prominent feature.
Therapeutic proof-of-concept in hiPSC-CMs: UPS inhibition increases wt-titin and improves contractility. CRISPR/Cas9 correction of TTNtv fully restores wt-titin, eliminates tr-titin, and recovers contractility — strongest proof-of-concept for gene correction therapy. (sources/TTN-CVResearch-2022, rating: high)
Metabolic shift and mTORC1 activation in TTNtv rat models: Rat models with TTNtv show decreased titin protein levels, metabolic shift from fatty acid oxidation to glycolysis, and mTORC1 (mammalian target of rapamycin complex 1) pathway activation — mirroring metabolic signatures seen in some patients with DCM. This supports the hypothesis that TTNtv carriers may be in a compensated state susceptible to decompensation under metabolic stress (pregnancy, alcohol). (sources/HF-Precision-Medicine-AHA-2019, rating: high)
Less cardiac hypertrophy than other genetic DCM forms: TTNtv-DCM patients develop less cardiac hypertrophy than patients with other genetic cardiomyopathies (e.g. LMNA, MYH7) when corrected for degree of cardiac function or dilatation — reflecting the metabolic-sarcomere mechanism rather than a hypertrophic remodelling response. (sources/DCM-Lancet-2023, rating: very high)
Metabolic shift in sarcomeric DCM: Sarcomere insufficiency (TTNtv and other sarcomere gene mutations including MYH7, TPM1, TNNT2) → increased metabolic demand + shift toward glucose utilisation + oxidative and mitochondrial stress. This metabolic signature is shared across sarcomere gene DCM, not specific to TTNtv. (sources/DCM-Lancet-2023, rating: very high)
Atrial myopathy hypothesis: TTNtv in early-onset AF may drive disease via atrial structural dysfunction rather than primary ion channel dysfunction — consistent with AF as an initial cardiomyopathy manifestation before ventricular involvement. (sources/eoaf-jama-2021, sources/genetic-eoaf-ehj-2024)

Clinical Phenotypes

Dilated Cardiomyopathy / NDLVC

TTNtv is the most common genetic cause of DCM (15–25% of DCM cohorts). Also the most common predisposition in restrictive, non-compaction, peripartum, alcoholic, and anthracycline-induced CMP. (sources/TTN-CVResearch-2022, rating: high)
Heterogeneous CMR pattern in NDLVC: TTN genotype shows heterogeneous LGE without the characteristic ring-like pattern of DSP/FLNC/PLN; often associated with lower LVEF. (sources/esc-cmp-2023)
Second-hit phenotypes: TTNtv confer markedly elevated CMP risk combined with environmental stressors — alcoholic CMP (13.5% TTNtv prevalence vs. 2.9% controls), cancer therapy-induced CMP (7.5% of cases), peripartum CMP (10% of patients). (sources/esc-cmp-2023)

Early-Onset Atrial Fibrillation

TTNtv in AF <40 without structural disease: In a prospective cohort of 122 patients with AF before age 40 (excluding structural heart disease), 4 of 8 P/LP variant carriers had TTN variants — making TTN the most common cardiomyopathy gene identified. CMR findings were normal. (sources/eoaf-riskfactor-ehj-2026, rating: medium)
Familial AF TTNtv cohort — no LV dysfunction at diagnosis: In a familial AF cohort with TTNtv and AF onset at median age 26, all variants were in cardiac isoforms. TTNtv carriers had normal LA and LV dimensions at AF diagnosis and at multi-year follow-up — strongest human evidence that TTNtv can cause clinically isolated AF in the complete absence of ventricular cardiomyopathy. (sources/genetic-af-dxmx-jce-2022, rating: medium)
AF precedes ventricular cardiomyopathy in ~50% of TTNtv carriers: In UK Biobank TTNtv carriers who eventually developed both AF and ventricular cardiomyopathy, AF was the first diagnosis in approximately 50% of cases — directly challenging the assumption that AF is a downstream sequela of established DCM. (sources/genetic-eoaf-ehj-2024, rating: high)
PRS modifies TTNtv AF penetrance 3-fold: In ~44,000 UK Biobank participants, TTNtv carriers in the highest PRS tertile had 21.5% AF prevalence vs. 6.7% in the lowest PRS tertile. Common variant background substantially modifies rare TTN loss-of-function penetrance for AF. (sources/genetic-eoaf-ehj-2024, rating: high)

Management Implications

Minimum genetic panel for DCM/HNDC (ESC 2021): TTN is a required gene alongside LMNA, MYH7, MYBPC3, TNNT2, RBM20, PLN, SCN5A, BAG3, and others. (sources/HF-ESC-2021, rating: very high)
LV reverse remodeling: Up to 70% of TTN-related DCM patients achieve LVEF improvement on standard HF therapy — the highest reverse remodeling rate among DCM genotypes. TRED-HF pilot data showed 44% relapse within 6 months after drug withdrawal in non-ischaemic DCM that achieved partial/complete LVEF recovery — caution against drug withdrawal in TTN patients who transiently improve. (sources/HF-ESC-2021, rating: very high)
Heightened arrhythmia risk: TTN is classified as one of 10 genes associated with heightened arrhythmia risk in cardiomyopathy (alongside LMNA, RBM20, RYR2, SCN5A, FLNC, DSP, PLN, DES, ABCC9), warranting more intensive cardiac monitoring and/or device intervention for AF, VT, and/or heart block. (sources/genetic-yield-jama-card-2022, rating: high)
Cardiomyopathy surveillance in EOAF carriers: AF precedes cardiomyopathy in ~50% of TTNtv carriers. Identifying a TTNtv in an EOAF patient should trigger longitudinal cardiomyopathy surveillance (CMR preferred), even when ventricular function is initially normal. (sources/genetic-eoaf-ehj-2024, rating: high)
TTNtv pLOF drives cardiomyopathy and HF risk in AF patients: In cause-specific Cox regression, pLOF variants in the 5 replicated AF genes were associated with cardiomyopathy (HR 3.13) and HF (HR 1.51) prior to AF diagnosis. When TTN variants were excluded, these associations became non-significant — confirming TTNtv as the primary driver. (sources/Biobank-AF-JAMA-2024, rating: high)
AF PRS does not predict cardiomyopathy: The common genetic AF PRS was not associated with cardiomyopathy (HR 0.99) or HF (HR 1.02) — confirming that rare TTN pLOF variants and common AF-PRS represent biologically distinct pathways. (sources/Biobank-AF-JAMA-2024, rating: high)

Contradictions / Open Questions

Pre-clinical PTM/PQC targeting has repeatedly failed in clinical trials: Multiple strategies that reduced titin stiffness in animal models (sildenafil/BNP via cGMP-PKG; sGC stimulators; RBM20 inhibition) failed in large clinical trials in human HFpEF (RELAX, VITALITY, SOCRATES). Whether this reflects animal-to-human biological differences, patient heterogeneity, dosing, or pathway compartmentalization is unresolved — no approved titin-targeted therapy currently exists. (sources/TTN-CVResearch-2022, rating: high)
Does TTNtv always progress to ventricular cardiomyopathy, or is atrial-limited disease possible? The JCE 2022 familial AF cohort showed normal LA/LV dimensions at diagnosis and follow-up, suggesting some TTNtv carriers may have purely atrial phenotypes. By contrast, EHJ 2024 UK Biobank shows AF precedes cardiomyopathy in ~50% of TTNtv carriers who develop both. Penetrance may vary by PRS background, environmental triggers, or variant type — the expected natural history and optimal surveillance interval for TTNtv carriers presenting with isolated EOAF is not established. (sources/genetic-af-dxmx-jce-2022, sources/genetic-eoaf-ehj-2024)
TTN LV reverse remodeling vs. arrhythmia risk paradox: ESC 2021 reports that TTN-associated DCM has both the highest LV reverse remodeling rate (up to 70%) and higher atrial/ventricular arrhythmia risk. Whether the reverse remodelers have lower arrhythmia burden is not characterized. (sources/HF-ESC-2021)
TTN missense variants excluded from clinical reporting — diagnostic gap: TTN missense variants are routinely excluded from clinical reporting, but this may miss rare pathogenic missense variants. There is no validated functional test to distinguish benign from pathogenic TTN missense variants in routine clinical practice. (sources/eoaf-jama-2021)
Second hit theory — penetrance context-dependent, counseling complexity: A TTNtv carrier who avoids environmental triggers (alcohol, cardiotoxic chemotherapy, pregnancy) may never develop clinical disease. Counseling TTNtv carriers about absolute vs. conditional risk for these triggers requires personalized communication not currently standardized in guidelines. (sources/esc-cmp-2023)

Connections

Related to entities/Atrial-Fibrillation
Related to entities/DCM
Related to entities/NDLVC
Related to concepts/Titin-Isoform-Switch
Related to concepts/Titin-PTMs
Related to concepts/Early-Onset-Atrial-Fibrillation
Related to concepts/Genetic-Testing-in-AF
Related to concepts/Genetic-Testing-in-Cardiomyopathy
Related to concepts/Arrhythmogenic-Cardiomyopathy
Related to sources/TTN-CVResearch-2022
Related to sources/eoaf-jama-2021
Related to sources/genetic-eoaf-ehj-2024
Related to sources/genetic-af-dxmx-jce-2022
Related to sources/Biobank-AF-JAMA-2024
Related to sources/genetic-yield-jama-card-2022
Related to sources/HF-ESC-2021
Related to sources/esc-cmp-2023
Related to sources/DCM-Lancet-2023